天津医药

• 细胞与分子生物学 • 上一篇    下一篇

舒尼替尼对人高转移肝癌细胞株MHCC97-H中局部粘着斑激酶表达水平的影响

张尘玉   

  1. 辽宁医学院附属第一医院肿瘤四科
  • 收稿日期:2013-07-23 修回日期:2014-01-10 出版日期:2014-05-15 发布日期:2014-05-15
  • 通讯作者: 张尘玉

The Expression Level Changes of ? Focal Adhesion Kinase With Sunitinib In Highly Metastatic MHCC97-H Hepatocellular Carcinoma Cell Lines

ZHANG chen yu   

  • Received:2013-07-23 Revised:2014-01-10 Published:2014-05-15 Online:2014-05-15
  • Contact: ZHANG chen yu

PDF (PC)

3017

摘要： 目的：探讨舒尼替尼对人高转移肝癌细胞株MHCC97-H的体外杀伤作用，以及对局部粘着斑激酶（Focal Adhesion Kinase，FAK）表达水平的影响。方法：采用瑞氏吉姆萨法染色观察用药前后肝癌细胞的形态学变化,MTT法检测高转移肝癌细胞株MHCC97-H的增殖抑制，用Western-Blot检测用药前后FAK的蛋白表达。结果：舒尼替尼对肝癌细胞株MHCC97-H有抑制作用，瑞氏吉姆萨法染色200倍光镜下可观察到染色质固缩、胞核碎裂及凋亡小体等典型的凋亡形态。药物作用48h时抑制率最明显，2.5、5、10和20umol/L浓度下抑制率分别为（32.9±1.5）%、（49.2±2.3）%、（63.8±2.8）%和（58.9±3.4）%，各组比较差异均有统计学意义。Western-Blot结果显示经不同浓度舒尼替尼作用48h后，FAK蛋白的表达水平分别降至对照组的85.51%、72.09%，57.61%、62.02%，差异有统计学意义（P＜0.05）。结论：舒尼替尼对肝癌细胞株MHCC97-H有抑制及促凋亡作用，并能降低FAK蛋白的表达。

关键词: 舒尼替尼, 肝细胞癌, 局部粘着斑激酶

Abstract: Objective:To explore sunitinib in highly metastatic hepatocellular carcinoma cell lines MHCC97-H in vitro cytotoxicity, as well as focal adhesion kinase (Focal Adhesion Kinase, FAK) expression levels.Methods:To observe the morphological changes of cells stained using Giemsa, to monitor highly metastatic hepatocellular carcinoma cell lines MHCC97-H inhibition by MTT assay，to detect the protein expression of FAK before and after treatment by Western-Blot. Results:Sunitinib on hepatoma cell lines MHCC97-H inhibition, Switzerland 400 times Giemsa staining can be observed under the light microscope chromatin condensation, nuclear fragmentation and apoptotic bodies and other typical apoptotic morphology. 48h drug inhibition rate the most obvious, 2.5, 5 and 20umol / L concentration inhibition rate were (32.9 ± 1.5)%, (49.2 ± 2.3)%, (63.8 ± 2.8)% and (58.9 ± 3.4) %, the group differences were statistically significant. Western-Blot results showed that different concentrations of sunitinib after 48h, FAK protein levels were reduced in 85.51%, 72.09%, 57.61%, 62.02% of the control group, the differences were statistically significant (P<0.05). Conclusion:Sunitinib on hepatocellular carcinoma to inhibit and induce apoptosis, and can reduce the expression of FAK.

Key words: sunitinib, hepatocellular carcinoma, Focal Adhesion Kinase